Evogene

Evogene Current Assets

The Current Assets of Evogene (EVGN) as of Oct 8, 2026 is 13.20 M USD. In the previous year, Current Assets was 22.95 M USD — a change of -42.49% (lower).

Current Assets

13.20 MUSD

YoY

-42.49%

Last updated:

Current Assets of Evogene is 2025 13.20 M USD. Current Assets of Evogene was 2024 22.95 M USD. It decreases by -42.49% lower compared to the previous year.

The Evogene Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
55.05 M USD
Jan 1, 2019
50.01 M USD
Jan 1, 2020
53.18 M USD
Jan 1, 2021
58.62 M USD
Jan 1, 2022
38.75 M USD
Jan 1, 2023
37.44 M USD
Jan 1, 2024
22.95 M USD
Jan 1, 2025
13.20 M USD
The Evogene Current Assets history
YEARCurrent AssetsYoY
13.20 MUSD-42.49%
22.95 MUSD-38.71%
37.44 MUSD-3.37%
38.75 MUSD-33.90%
58.62 MUSD+10.21%
53.18 MUSD+6.35%
50.01 MUSD-9.15%
55.05 MUSD-14.65%
64.49 MUSD-15.61%
76.43 MUSD-10.93%
85.80 MUSD-3.99%
89.37 MUSD-30.61%
128.78 MUSD+383.59%
26.63 MUSD+1,419.11%
1.75 MUSD-35.10%
2.70 MUSD+172.83%
990,000.00USD-56.83%
2.29 MUSD+452.53%
415,000.00USD+1,575.57%
24,767.62USD—
Access this data via the Eulerpool API

Evogene Stock analysis

What does Evogene do? Evogene Ltd is an Israeli biotechnology company that focuses on the application of computational biology and genomics to agriculture and biology. The company originated from a spin-off of the Weizmann Institute of Science and was founded in 2002. Today, it is a leading global provider of biotechnology solutions for the agriculture and biotechnology industry. Evogene's business model is based on providing innovative technologies and services for its customers, aiming to improve plant development, particularly in terms of resistance to environmental stress factors and pests. To achieve this, the company utilizes modern biotechnology methods and leverages artificial intelligence. It employs advanced machine learning and large-scale data analysis techniques to gain a better understanding of underlying biological processes. Evogene operates in three core areas: agricultural biotechnology, drug discovery biotechnology, and biomaterials. The company is capable of offering customized biological solutions tailored to the specific needs of its customers. Agricultural biotechnology is one of Evogene's key sectors. It utilizes state-of-the-art technologies and methods to generate plant resistance to pests and environmental factors. With the help of a reliable pipeline of innovative products such as seeds, biostimulants, and fertilizers, Evogene aims to play an important role in food security, environmental sustainability, and resilience to climate change. The company has a strong product pipeline aimed at improving nutrient efficiency of crops while reducing environmental impact from pesticide and fertilizer use. One such product resulting from this pipeline is EvoCanna, which utilizes modern genomics methods to optimize hemp plants in terms of phytocannabinoid biosynthesis. The goal of Evogene's drug discovery biotechnology and biomaterials sector is to develop innovative and effective medicines for diseases such as cancer and obesity. The company utilizes modern machine learning and large-scale data analysis methods to identify the potential of new drug candidates. In the biomaterials sector, Evogene aims to develop innovative technologies and solutions for better and more sustainable use of natural resources. An important application of this concept is biostimulants, which can improve the growth rate, stress tolerance, and yield of crops. Additionally, the company can offer new materials and environmentally friendly solutions in the packaging industry. Overall, Evogene has achieved impressive success in recent years and established itself as a leading biotechnology company. By utilizing cutting-edge technologies, methods, and scientific concepts, particularly artificial intelligence and machine learning, and by operating as a responsible company in the fields of agriculture, biomaterials, and programming, Evogene is able to offer innovative biotechnological solutions. The company is currently well-equipped and has a promising pipeline of groundbreaking innovation projects that embody the desire for a sustainable worldview. Evogene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Evogene stock

Current Assets of Evogene is 13.20 M USD in 2025.

Current Assets of Evogene changed from 22.95 M USD to 13.20 M USD, representing a -42.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Evogene since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Evogene historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Evogene

All Key Metrics — Evogene